Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s claims about the boxed warning (rodent GLP-1–dependent thyroid C-cell tumors, orforglipron being not pharmacologically active in rats/mice and not producing tumors, human relevance not determined, and uncertain value of routine calcitonin/ultrasound monitoring) are directly supported by the provided label text, with no contradictions identified.
Category Scores
Accurate Statements
The boxed warning states that in products with GLP-1 receptor agonist activity pharmacologically active in rats and mice, rodent thyroid C-cell tumors are observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents.
Boxed Warning (Warning: Risk of Thyroid C-Cell Tumors)
The boxed warning states that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents.
Boxed Warning (Warning: Risk of Thyroid C-Cell Tumors); also consistent with Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)
The boxed warning states that while orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of rodent GLP-1 receptor-dependent thyroid C-cell tumors has not been determined.
Boxed Warning (Warning: Risk of Thyroid C-Cell Tumors); also in Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)
The boxed warning states that routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with FOUNDAYO.
Boxed Warning (Warning: Risk of Thyroid C-Cell Tumors)
Unsupported Statements
Contradictions
Important Omissions
The AI response does not evaluate/quote the boxed warning’s counseling and symptom examples (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness) or the specific statements about uncertain value rationale (calcitonin test specificity and background incidence), even though these are part of the boxed warning content.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response is a label-alignment assessment focused on boxed-warning language; it does not introduce dosing, monitoring actions, or treatment recommendations beyond stating that the label describes monitoring as of uncertain value.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Does not cover every boxed-warning counseling detail (symptom examples and the stated rationale for uncertain monitoring value).
Suggested Improvement
Explicitly include and verify the boxed-warning counseling/symptom examples and the monitoring-uncertainty rationale wording when assessing full boxed-warning alignment.